Last reviewed · How we verify
Truvada and Isentress
Truvada is a combination of emtricitabine and tenofovir disoproxil fumarate, which are nucleoside reverse transcriptase inhibitors (NRTIs) used to treat HIV-1 infection. Isentress is a HIV integrase strand transfer inhibitor (INSTI) used to treat HIV-1 infection.
Truvada is a combination of emtricitabine and tenofovir disoproxil fumarate, which are nucleoside reverse transcriptase inhibitors (NRTIs) used to treat HIV-1 infection. Isentress is a HIV integrase strand transfer inhibitor (INSTI) used to treat HIV-1 infection. Used for Treatment of HIV-1 infection, Prevention of HIV-1 infection in high-risk individuals.
At a glance
| Generic name | Truvada and Isentress |
|---|---|
| Sponsor | Projeto Praça Onze |
| Drug class | NRTI and INSTI |
| Target | Reverse transcriptase and integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Truvada works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of retroviruses like HIV. Isentress works by inhibiting the integrase enzyme, which is also essential for the replication of retroviruses like HIV. By inhibiting these enzymes, Truvada and Isentress prevent the virus from replicating and reduce the viral load in the body.
Approved indications
- Treatment of HIV-1 infection
- Prevention of HIV-1 infection in high-risk individuals
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Abdominal pain
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Post-Exposure Prophylaxis in Health Care Workers (PHASE4)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
- A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Truvada and Isentress CI brief — competitive landscape report
- Truvada and Isentress updates RSS · CI watch RSS
- Projeto Praça Onze portfolio CI